![logo](/logos/RCUS.webp)
Arcus Biosciences, Inc.
NYSE:RCUS
15.72 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Arcus Biosciences, Inc. |
Symbool | RCUS |
Munteenheid | USD |
Prijs | 15.72 |
Beurswaarde | 1,437,240,300 |
Dividendpercentage | 0% |
52-weken bereik | 12.95 - 21.785 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Terry J. Rosen Ph.D. |
Website | https://www.arcusbio.com |
An error occurred while fetching data.
Over Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)